Difference between revisions of "Part:BBa K5059000"

 
Line 3: Line 3:
 
<partinfo>BBa_K5059000 short</partinfo>
 
<partinfo>BBa_K5059000 short</partinfo>
  
−
This sequence resembles the MdOSC2 variant of the alpha-amyrin synthase from Malus domestica. Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway. Since yeast doesn't contain AAS, we integrated this sequence into the yeast genome to successfully produce ursolic acid. We also added a 6x-His tag at the end of the sequence to enable Ni-NTA chromatography.
+
This sequence resembles the MdOSC2 variant of the alpha-amyrin synthase from ""Malus domestica"". Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway. Since yeast doesn't contain AAS, we integrated this sequence into the yeast genome to successfully produce ursolic acid. We also added a 6x-His tag at the end of the sequence to enable Ni-NTA chromatography.
  
−
<!-- Add more about the biology of this part here
 
−
===Usage and Biology===
 
  
 +
===Sequence and Features===
 
<!-- -->
 
<!-- -->
−
<span class='h3bb'>Sequence and Features</span>
 
 
<partinfo>BBa_K5059000 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K5059000 SequenceAndFeatures</partinfo>
−
 
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  
Line 17: Line 14:
 
<partinfo>BBa_K5059000 parameters</partinfo>
 
<partinfo>BBa_K5059000 parameters</partinfo>
 
<!-- -->
 
<!-- -->
 +
 +
===Usage and Biology===
 +
Ursolic acid has gained traction recently as a potential therapeutic agent. Preliminary studies have been done on ursolic acid, determining that it has therapeutic potential for cancer, liver disease, and obesity, among other health benefits [1]. There is particular interest in ursolic acid's properties to fight cancer, as it is an antioxidant and anti-inflammatory agent.

Revision as of 04:20, 20 September 2024


Alpha-Amyrin Synthase (AAS)

This sequence resembles the MdOSC2 variant of the alpha-amyrin synthase from ""Malus domestica"". Alpha-amyrin synthase (AAS) converts 2,3-oxidosqualene to alpha-amyrin, the precursor for ursolic acid in the mevalonate pathway. Since yeast doesn't contain AAS, we integrated this sequence into the yeast genome to successfully produce ursolic acid. We also added a 6x-His tag at the end of the sequence to enable Ni-NTA chromatography.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Usage and Biology

Ursolic acid has gained traction recently as a potential therapeutic agent. Preliminary studies have been done on ursolic acid, determining that it has therapeutic potential for cancer, liver disease, and obesity, among other health benefits [1]. There is particular interest in ursolic acid's properties to fight cancer, as it is an antioxidant and anti-inflammatory agent.